EP3773747A4 - USE OF EXOSOMES FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS - Google Patents

USE OF EXOSOMES FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS Download PDF

Info

Publication number: EP3773747A4
Authority: EP; European Patent Office
Prior art keywords: exosomes; therapeutic agents; targeted delivery; targeted; delivery
Prior art date: 2018-03-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP19776678.5A

Other languages

German (de)

French (fr)

Other versions

EP3773747A1 (en

Inventor

Raghu Kalluri

Valerie LEBLEU

Pedro CORREA DE SAMPAIO

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Texas System

University of Texas at Austin

Original Assignee

University of Texas System

University of Texas at Austin

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-03-28

Filing date

2019-03-28

Publication date

2022-02-23

2019-03-28 Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System

2021-02-17 Publication of EP3773747A1 publication Critical patent/EP3773747A1/en

2022-02-23 Publication of EP3773747A4 publication Critical patent/EP3773747A4/en

Status Pending legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

EP19776678.5A 2018-03-28 2019-03-28 USE OF EXOSOMES FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS Pending EP3773747A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201862649057P	2018-03-28	2018-03-28
PCT/US2019/024603 WO2019191444A1 (en)	2018-03-28	2019-03-28	Use of exosomes for targeted delivery of therapeutic agents

Publications (2)

Publication Number	Publication Date
EP3773747A1 EP3773747A1 (en)	2021-02-17
EP3773747A4 true EP3773747A4 (en)	2022-02-23

Family

ID=68060505

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP19776678.5A Pending EP3773747A4 (en)	2018-03-28	2019-03-28	USE OF EXOSOMES FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS

Country Status (7)

Country	Link
EP (1)	EP3773747A4 (en)
JP (1)	JP7813099B2 (en)
KR (1)	KR20200136978A (en)
CN (1)	CN112533643A (en)
AU (1)	AU2019243179B2 (en)
CA (1)	CA3095136A1 (en)
WO (1)	WO2019191444A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3775258A4 (en)	2018-03-28	2022-01-26	Board of Regents, The University of Texas System	IDENTIFICATION OF EPIGENETIC ALTERATIONS IN DNA ISOLATED FROM EXOSOMES
IT201900007785A1 (en) *	2019-05-31	2020-12-01	Univ Degli Studi Milano	Extracellular vesicles to deliver therapeutic or diagnostic drugs
JP7674354B2 (en) *	2019-12-05	2025-05-09	ボードオブリージェンツ，ザユニバーシティオブテキサスシステム	Exosome-Based Therapies for Liver Fibrosis and Other Fibrosis-Related Diseases
WO2021119552A1 (en) *	2019-12-13	2021-06-17	Lawrence Livermore National Security, Llc	Nanotube-vesicle compositions and uses thereof
US12311053B2 (en)	2019-12-13	2025-05-27	Lawrence Livermore National Security, Llc	Nanotube-vesicle compositions and uses thereof
CN117860902B (en) *	2021-11-17	2024-07-16	中国人民解放军空军军医大学	A prostate cancer molecular targeting system and its construction method and application
CN114774471A (en) *	2022-05-10	2022-07-22	厦门星际诺康细胞科技有限公司	IL 27-presenting stable cell and construction method thereof, IL 27-presenting engineered exosome and preparation method and application thereof
KR20250171535A (en) *	2024-05-29	2025-12-09	사회복지법인 삼성생명공익재단	A method of manufacturing extracellular vesicles for wound healing using electroporation
WO2026002276A1 (en) *	2024-06-28	2026-01-02	艾码生物科技(南京)有限公司	Tgfb-targeting rna interference method, nucleic acid and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015085096A1 (en) *	2013-12-04	2015-06-11	Board Of Regents, The University Of Texas System	Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis
WO2016201323A1 (en) *	2015-06-10	2016-12-15	Board Of Regents, The University Of Texas System	Use of exosomes for the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7473678B2 (en) *	2004-10-14	2009-01-06	Biomimetic Therapeutics, Inc.	Platelet-derived growth factor compositions and methods of use thereof
US9085778B2 (en) *	2006-05-03	2015-07-21	VL27, Inc.	Exosome transfer of nucleic acids to cells
GB201121069D0 (en) *	2011-12-07	2012-01-18	Isis Innovation	Delivery system
ES2686129T3 (en) *	2012-11-13	2018-10-16	Codiak Biosciences, Inc.	Administration of therapeutic agents
CN104822390A (en) *	2012-11-29	2015-08-05	耶达研究及发展有限公司	Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors
JP2019501179A (en) *	2015-12-30	2019-01-17	ザリージェンツオブザユニバーシティオブカリフォルニア	Methods for improved production and isolation of cell-derived vesicles
TWI601741B (en) *	2016-07-11	2017-10-11	財團法人國家衛生研究院	Method of producing exosomes by using ep4-antagonist to induce exosomes releasing from stem cells and the use thereof

2019
- 2019-03-28 JP JP2020551798A patent/JP7813099B2/en active Active
- 2019-03-28 EP EP19776678.5A patent/EP3773747A4/en active Pending
- 2019-03-28 CA CA3095136A patent/CA3095136A1/en active Pending
- 2019-03-28 CN CN201980034058.9A patent/CN112533643A/en active Pending
- 2019-03-28 KR KR1020207030993A patent/KR20200136978A/en not_active Ceased
- 2019-03-28 AU AU2019243179A patent/AU2019243179B2/en active Active
- 2019-03-28 WO PCT/US2019/024603 patent/WO2019191444A1/en not_active Ceased

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015085096A1 (en) *	2013-12-04	2015-06-11	Board Of Regents, The University Of Texas System	Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis
WO2016201323A1 (en) *	2015-06-10	2016-12-15	Board Of Regents, The University Of Texas System	Use of exosomes for the treatment of disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019191444A1 *
SHIN-ICHIRO OHNO ET AL: "Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells", MOLECULAR THERAPY, vol. 21, no. 1, 1 January 2013 (2013-01-01), US, pages 185 - 191, XP055501314, ISSN: 1525-0016, DOI: 10.1038/mt.2012.180 *

Also Published As

Publication number	Publication date
JP2021519296A (en)	2021-08-10
WO2019191444A1 (en)	2019-10-03
AU2019243179A1 (en)	2020-11-12
EP3773747A1 (en)	2021-02-17
JP7813099B2 (en)	2026-02-12
KR20200136978A (en)	2020-12-08
CA3095136A1 (en)	2019-10-03
AU2019243179B2 (en)	2025-09-18
CN112533643A (en)	2021-03-19

Legal Events

Date	Code	Title	Description
2019-10-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2021-01-15	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2021-01-15	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2021-02-17	17P	Request for examination filed	Effective date: 20200930
2021-02-17	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2021-02-17	AX	Request for extension of the european patent	Extension state: BA ME
2021-07-07	DAV	Request for validation of the european patent (deleted)
2021-07-07	DAX	Request for extension of the european patent (deleted)
2022-02-23	A4	Supplementary search report drawn up and despatched	Effective date: 20220124
2022-02-23	RIC1	Information provided on ipc code assigned before grant	Ipc: C12N 15/113 20100101ALI20220118BHEP Ipc: C12N 15/87 20060101ALI20220118BHEP Ipc: A61K 48/00 20060101AFI20220118BHEP

Publication	Publication Date	Title
EP3773747A4 (en)	2022-02-23	USE OF EXOSOMES FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS
EP3813853A4 (en)	2022-04-06	COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE THEREOF
EP3840730A4 (en)	2021-12-22	COMPOSITIONS FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS AND THEIR METHODS OF USE AND METHODS OF PREPARATION
EP3634506A4 (en)	2021-03-10	DRESSING FOR WOUND SURVEILLANCE AND THERAPEUTIC AGENT ADMINISTRATION
EP3817696A4 (en)	2022-03-30	TOPICAL OCULAR DELIVERY DEVICES AND METHODS OF USE THEREOF
EP3826589A4 (en)	2022-04-20	OPHTHALMIC DEVICE FOR THE DELIVERY OF MEDICINES
EP3817747A4 (en)	2022-07-06	TARGETED DELIVERY OF THERAPEUTIC AGENTS TO HUMAN ADIPOCYTES
MA51796A (en)	2020-12-16	METHODS AND COMPOSITIONS FOR THE ADMINISTRATION OF THERAPEUTIC PROTEINS
MA50557A (en)	2020-09-16	PISTONS FOR DRUG DELIVERY DEVICES
EP3740272A4 (en)	2021-10-20	INJECTION PORT FOR THERAPEUTIC ADMINISTRATION
EP3256149A4 (en)	2019-08-14	FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS
EP3921420A4 (en)	2022-11-16	DRUG DELIVERY COMPOSITIONS FOR OCULAR DELIVERY OF THERAPEUTIC AGENTS AND METHODS OF USE THEREOF
EP3697481A4 (en)	2021-07-14	NASAL MEDICINAL DELIVERY EQUIPMENT AND METHODS OF USE
EP3621656A4 (en)	2021-01-27	FORMULATION FOR THE ADMINISTRATION OF AN EYE MEDICINE
EP3836866A4 (en)	2022-06-15	SYSTEMS FOR THE ENTERIC DELIVERY OF THERAPEUTIC AGENTS
EP3731846A4 (en)	2022-03-02	DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF INFECTIONS
EP3324944A4 (en)	2019-04-03	INTRAVITRANE DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF OCULAR CONDITIONS
EP3325081A4 (en)	2019-04-10	METHODS FOR LYMPHATIC DELIVERY OF ACTIVE PRINCIPLES
EP3509573A4 (en)	2020-04-29	PHARMACEUTICAL COMPOSITIONS FOR THE DELIVERY OF A PEPTIDE
EP3498280A4 (en)	2020-03-18	ADMINISTRATION AND DOSAGE OF A THERAPEUTIC AGENT FOR ENDOMETRIOSIS
EP3852655A4 (en)	2022-06-22	EXPANDABLE EXOSKELETON DEVICES FOR DRUG DELIVERY
EP3672587A4 (en)	2021-05-19	PHARMACEUTICAL COMPOSITIONS INTENDED FOR THE TREATMENT OF OPHTHALMIC DISORDERS
EP3405151A4 (en)	2019-09-11	IMPROVED TRANSDERMAL DELIVERY OF ACTIVE AGENTS
EP3500291A4 (en)	2020-03-11	FORMULATIONS FOR THE ORAL ADMINISTRATION OF ACTIVE AGENTS
EP3490548A4 (en)	2020-04-15	ADMINISTRATION OF HYPOXIA-ACTIVATED DRUGS IN COMBINATION WITH IMMUNOMODULATORS FOR THE TREATMENT OF CANCER